

# Andrew M Evens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5698032/publications.pdf>

Version: 2024-02-01

275  
papers

13,649  
citations

23544

58  
h-index

24961

109  
g-index

277  
all docs

277  
docs citations

277  
times ranked

16222  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	0.6	829
2	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	13.5	804
3	The genetic landscape of mutations in Burkitt lymphoma. <i>Nature Genetics</i> , 2012, 44, 1321-1325.	9.4	517
4	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1398-1403.	3.3	494
5	Pure Red-Cell Aplasia and Epoetin Therapy. <i>New England Journal of Medicine</i> , 2004, 351, 1403-1408.	13.9	398
6	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
7	An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. <i>Annals of Oncology</i> , 2013, 24, 257-263.	0.6	318
8	Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. <i>Annals of Oncology</i> , 2011, 22, 1170-1180.	0.6	302
9	Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 1038-1046.	0.8	290
10	Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 173-183.	1.2	253
11	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
12	T-cell non-Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 1255-1264.	0.6	208
13	Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. <i>Bone Marrow Transplantation</i> , 2007, 40, 451-456.	1.3	205
14	Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. <i>Bone Marrow Transplantation</i> , 2007, 39, 425-429.	1.3	202
15	Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. <i>Cancer</i> , 2007, 109, 1532-1535.	2.0	197
16	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , 2010, 116, e118-e127.	0.6	188
17	Oxidative stress and apoptosis: a new treatment paradigm in cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 300.	3.0	182
18	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016, 128, 2199-2205.	0.6	166

#	ARTICLE	IF	CITATIONS
19	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. <i>Leukemia Research</i> , 2007, 31, 599-604.	0.4	164
20	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	7.7	163
21	The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. <i>Leukemia Research</i> , 2004, 28, 891-900.	0.4	161
22	Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. <i>Bone Marrow Transplantation</i> , 2007, 40, 185-192.	1.3	157
23	Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era. <i>American Journal of Transplantation</i> , 2013, 13, 1512-1522.	2.6	150
24	Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations. <i>Current Treatment Options in Oncology</i> , 2012, 13, 122-136.	1.3	145
25	A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. <i>Blood</i> , 2012, 119, 692-695.	0.6	138
26	Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2555.	3.8	134
27	Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy. <i>Current Oncology Reports</i> , 2010, 12, 383-394.	1.8	133
28	Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. <i>British Journal of Haematology</i> , 2006, 135, 642-650.	1.2	127
29	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014, 25, 2211-2217.	0.6	126
30	Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 113-122.	3.2	119
31	The Research on Adverse Drug Events and Reports (RADAR) Project. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2131.	3.8	111
32	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <i>tanford</i> in older <i>odgkin</i> lymphoma patients: a comprehensive analysis from the <i>orth</i> <i>American</i> intergroup trial <i>E</i> 2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	1.2	111
33	Treatment of Hodgkin lymphoma: the past, present, and future. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 543-556.	4.3	105
34	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	0.8	102
35	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i> , 2005, 106, 3343-3347.	0.6	101
36	Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1653-1659.	0.8	101

#	ARTICLE	IF	CITATIONS
37	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98
38	Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4132-4139.	0.8	93
39	PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- $\kappa$ B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. <i>Clinical Cancer Research</i> , 2009, 15, 3354-3365.	3.2	92
40	Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). <i>Leukemia</i> , 2015, 29, 886-894.	3.3	92
41	Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. <i>Bone Marrow Transplantation</i> , 2004, 34, 561-571.	1.3	91
42	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014, 165, 358-363.	1.2	91
43	Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of <i>Andrographis paniculata</i> . <i>Clinical Cancer Research</i> , 2010, 16, 4755-4768.	3.2	87
44	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	0.6	86
45	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 1318-1326.	0.6	85
46	Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. <i>Annals of Oncology</i> , 2012, 23, 2128-2137.	0.6	84
47	Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. <i>Cancer</i> , 2012, 118, 3743-3748.	2.0	82
48	Analysis of very elderly ( $\geq 80$ years) non-Hodgkin lymphoma: impact of functional status and comorbidities on outcome. <i>British Journal of Haematology</i> , 2012, 156, 196-204.	1.2	81
49	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-508.	0.8	78
50	Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. <i>Bone Marrow Transplantation</i> , 2006, 37, 997-1001.	1.3	75
51	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019, 37, 471-480.	0.8	74
52	Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. <i>Blood</i> , 2005, 105, 1265-1273.	0.6	71
53	G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , 2007, 137, 545-552.	1.2	71
54	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	2.0	71

#	ARTICLE	IF	CITATIONS
55	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	1.2	71
56	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 1059-1066.	3.2	71
57	The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2019, 10, 2030-2040.	0.8	66
58	Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 971-983.	2.0	65
59	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	2.5	62
60	Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab. <i>Cancer</i> , 2013, 119, 3662-3671.	2.0	61
61	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. <i>Nature Communications</i> , 2018, 9, 829.	5.8	60
62	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
63	Hypoxia-Inducible Factor-1 $\beta$ Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	0.8	57
64	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	2.0	56
65	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. <i>Oncotarget</i> , 2016, 7, 59976-59986.	0.8	56
66	CD23+ Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 166-177.	0.4	54
67	Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. <i>Blood</i> , 2015, 125, 2471-2476.	0.6	53
68	Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 576-580.	1.1	52
69	Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?. <i>Bone Marrow Transplantation</i> , 2006, 38, 95-100.	1.3	52
70	Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. <i>Blood</i> , 2014, 123, 2895-2897.	0.6	52
71	Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. <i>Journal of Controlled Release</i> , 2019, 295, 21-30.	4.8	52
72	Clinical, Morphologic, Immunophenotypic, and Molecular Cytogenetic Assessment of CD4 <sup>+</sup> /CD8 <sup>+</sup> T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2011, 136, 289-299.	0.4	51

#	ARTICLE	IF	CITATIONS
73	Expression of $CD25$ independently predicts early treatment failure of acute myeloid leukaemia ( $AML$ ). British Journal of Haematology, 2013, 160, 262-266.	1.2	49
74	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. British Journal of Haematology, 2008, 140, 385-393.	1.2	47
75	Rituximab-induced late onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor $Fc\gamma R3$ 158(V/F) polymorphism. American Journal of Hematology, 2010, 85, 810-812.	2.0	47
76	Health-related quality of life in Hodgkin lymphoma: a systematic review. Health and Quality of Life Outcomes, 2016, 14, 114.	1.0	47
77	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer, 2018, 124, 136-144.	2.0	47
78	Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood, 2003, 102, 297-302.	0.6	46
79	Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent. Clinical Cancer Research, 2004, 10, 1481-1491.	3.2	46
80	Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes. Clinical Cancer Research, 2010, 16, 719-726.	3.2	46
81	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Annals of Oncology, 2013, 24, 3076-3081.	0.6	45
82	Evaluation of Serious Adverse Drug Reactions. Archives of Internal Medicine, 2007, 167, 1041.	4.3	43
83	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biology of Blood and Marrow Transplantation, 2016, 22, 1543-1551.	2.0	42
84	The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood, 2011, 118, 1052-1061.	0.6	41
85	$^{18}F$ -FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem cell transplantation for relapsed and refractory Hodgkin lymphoma. British Journal of Haematology, 2014, 165, 793-800.	1.2	41
86	Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. British Journal of Haematology, 2008, 141, 676-680.	1.2	40
87	All-trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. British Journal of Haematology, 2010, 150, 158-169.	1.2	40
88	A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory $DLBCL$ and peripheral T-cell lymphomas. British Journal of Haematology, 2013, 163, 55-61.	1.2	39
89	De novo $CD5+$ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. American Journal of Hematology, 2016, 91, 395-399.	2.0	39
90	Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. Frontiers in Immunology, 2017, 8, 1736.	2.2	39

#	ARTICLE	IF	CITATIONS
91	Obesity and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , 2007, 18, 677-685.	0.8	37
92	Early Posttransplant Lymphoproliferative Disease. <i>American Journal of Clinical Pathology</i> , 2012, 138, 568-578.	0.4	37
93	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
94	Targeting angiogenesis for the treatment of sarcoma. <i>Current Opinion in Oncology</i> , 2006, 18, 354-359.	1.1	36
95	The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. <i>American Journal of Hematology</i> , 2014, 89, 633-638.	2.0	36
96	The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. <i>Leukemia and Lymphoma</i> , 2014, 55, 2778-2784.	0.6	36
97	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Blood</i> , 2014, 124, 3356-3364.	0.6	36
98	Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. <i>Scientific Reports</i> , 2018, 8, 744.	1.6	36
99	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	0.6	35
100	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. <i>Cancer Research</i> , 2016, 76, 3319-3331.	0.4	34
101	Treatment of T-cell non-hodgkin lymphoma. <i>Current Treatment Options in Oncology</i> , 2004, 5, 289-303.	1.3	33
102	Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?. <i>Bone Marrow Transplantation</i> , 2005, 35, 243-246.	1.3	33
103	Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 1291-1304.	3.3	33
104	Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. <i>American Journal of Hematology</i> , 2016, 91, 560-565.	2.0	32
105	Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1434-1441.	0.6	31
106	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw249.	3.0	31
107	Hodgkin lymphoma in older patients: an uncommon disease in need of study. <i>Oncology</i> , 2008, 22, 1369-79.	0.4	31
108	Comparative Analysis of Flow Cytometric Techniques in Assessment of ZAP-70 Expression in Relation to VH Mutational Status in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2007, 127, 182-191.	0.4	30

#	ARTICLE	IF	CITATIONS
109	Sun exposure and non-Hodgkin lymphoma: A population-based, caseâ€“control study. <i>European Journal of Cancer</i> , 2007, 43, 2388-2395.	1.3	30
110	Periodontal disease and risk of nonâ€“Hodgkin lymphoma in the Health Professionals Followâ€“Up Study. <i>International Journal of Cancer</i> , 2017, 140, 1020-1026.	2.3	29
111	TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology.. <i>Transplantation</i> , 2002, 74, 885-887.	0.5	28
112	Maintenance rituximab or observation after frontline treatment with bendamustineâ€“rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
113	Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2007, 18, 679-688.	0.6	26
114	Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2011, 22, 1183-1195.	0.8	25
115	How I manage patients with grey zone lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 345-350.	1.2	25
116	Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. <i>Scientific Reports</i> , 2019, 9, 17161.	1.6	25
117	Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2008, 19, 859-867.	0.8	24
118	Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 465-471.	2.3	24
119	Older patients (aged â‰¥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. <i>Haematologica</i> , 2022, 107, 1086-1094.	1.7	24
120	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
121	Vaccination history and risk of non-hodgkin lymphoma: a population-based, caseâ€“control study. <i>Cancer Causes and Control</i> , 2009, 20, 517-523.	0.8	23
122	<scp>Câ€“MYC</scp>â€“positive relapsed and refractory, diffuse large <scp>B</scp>â€“cell lymphoma: Impact of additional â€œhitsâ€“and outcomes with subsequent therapy. <i>Cancer</i> , 2017, 123, 4411-4418.	2.0	23
123	How Can Outcomes Be Improved for Older Patients With Hodgkin Lymphoma?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1502-1505.	0.8	22
124	The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models. <i>Clinical Cancer Research</i> , 2014, 20, 6023-6033.	3.2	21
125	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	1.7	21
126	Clinical characteristics of erythropoietin-associated pure red cell aplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 467-472.	0.7	20



#	ARTICLE	IF	CITATIONS
127	Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 481-489.	0.7	20
128	Burkitt's and Burkitt-like Lymphoma. <i>Current Treatment Options in Oncology</i> , 2002, 3, 291-305.	1.3	18
129	The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. <i>Cancer Informatics</i> , 2015, 14, CIN.S34144.	0.9	18
130	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. <i>Oncotarget</i> , 2018, 9, 22693-22702.	0.8	18
131	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019, 60, 894-903.	0.6	18
132	Paradoxical Regulation of Hypoxia Inducible Factor-1 $\alpha$ (HIF-1 $\alpha$ ) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e81333.	1.1	18
133	A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0170521.	1.1	18
134	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase III study. <i>British Journal of Haematology</i> , 2014, 166, 514-520.	1.2	17
135	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018, 182, 212-221.	1.2	17
136	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	0.6	17
137	Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic Options. <i>Current Treatment Options in Oncology</i> , 2007, 8, 352-374.	1.3	16
138	Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. <i>British Journal of Haematology</i> , 2010, 150, 365-369.	1.2	16
139	Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. <i>Leukemia and Lymphoma</i> , 2013, 54, 497-502.	0.6	16
140	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
141	Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. <i>Current Treatment Options in Oncology</i> , 2005, 6, 289-296.	1.3	15
142	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 684-692.e3.	0.2	15
143	Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide's "Off-Label" Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns. <i>Blood</i> , 2005, 106, 2244-2244.	0.6	15
144	Molecular etiology of mature T-cell non-hodgkins lymphomas. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, d156-175.	3.0	14

#	ARTICLE	IF	CITATIONS
145	The Challenges of Epidemiologic Research in Non-Hodgkin Lymphoma. JAMA - Journal of the American Medical Association, 2008, 300, 2059.	3.8	14
146	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. Clinical Cancer Research, 2009, 15, 6462-6471.	3.2	14
147	Chemotherapeutic Advancements in Peripheral T-Cell Lymphoma. Seminars in Hematology, 2014, 51, 17-24.	1.8	14
148	The evolving role of response-adapted PET imaging in Hodgkin lymphoma. Therapeutic Advances in Hematology, 2016, 7, 108-125.	1.1	14
149	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leukemia and Lymphoma, 2010, 51, 1163-1177.	0.6	13
150	XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematological Oncology, 2013, 31, 69-75.	0.8	13
151	Management of older Hodgkin lymphoma patients. Hematology American Society of Hematology Education Program, 2019, 2019, 233-242.	0.9	12
152	Gray Zone Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1251-1260.	0.9	11
153	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Advances, 2021, 5, 3623-3632.	2.5	11
154	Sustained Hematologic and Central Nervous System Remission with Single-Agent Denileukin Diftitox in Refractory Adult T-Cell Leukemia/Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 472-474.	1.4	10
155	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology American Society of Hematology Education Program, 2014, 2014, 135-143.	0.9	10
156	Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissue. Journal of Radiation Research, 2015, 56, 792-803.	0.8	10
157	First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. British Journal of Haematology, 2020, 190, 222-235.	1.2	10
158	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. Blood, 2018, 132, 1618-1618.	0.6	10
159	A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). Blood, 2012, 120, 55-55.	0.6	10
160	Current Therapeutic Strategies and New Treatment Paradigms for Follicular Lymphoma. Cancer Treatment and Research, 2015, 165, 197-226.	0.2	9
161	Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study. Blood, 2014, 124, 3096-3096.	0.6	9
162	Diffuse Large B-Cell Lymphomas Utilize Endogenous and Exogenous Fatty Acids for Cell Growth and Survival. Blood, 2012, 120, 1581-1581.	0.6	9

#	ARTICLE	IF	CITATIONS
163	Checkpoint inhibitor immunotherapy during pregnancy for relapsed refractory Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2022, 97, 833-838.	2.0	9
164	Current Treatment Options for Older Patients with Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 42.	1.3	8
165	SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. <i>Cancer</i> , 2021, 127, 1926-1932.	2.0	8
166	Pre-diagnosis cigarette smoking and overall survival in non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 352-356.	1.2	7
167	Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma. <i>British Journal of Haematology</i> , 2020, 188, 295-308.	1.2	7
168	How I treat advanced Hodgkin lymphoma – a global view. <i>British Journal of Haematology</i> , 2020, 190, 837-850.	1.2	7
169	Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998). <i>Blood</i> , 2010, 116, 702-702.	0.6	7
170	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 640-640.	0.6	7
171	Oncogenic Integration of Nucleotide Metabolism via Fatty Acid Synthase in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 725137.	1.3	7
172	FDG-PET imaging for Hodgkin lymphoma: current use and future applications. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 20-35.	0.3	7
173	Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. <i>Blood</i> , 2009, 114, 2726-2726.	0.6	6
174	Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma. <i>JAMA Network Open</i> , 2021, 4, e2128373.	2.8	6
175	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.2	6
176	Primary mediastinal large B-cell lymphoma in HIV: report of two cases. <i>Journal of Hematopathology</i> , 2009, 2, 45-49.	0.2	5
177	Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder. <i>Annals of Hematology</i> , 2015, 94, 893-894.	0.8	5
178	Important new developments in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 6-6.	1.2	5
179	Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches. <i>Current Oncology Reports</i> , 2020, 22, 113.	1.8	5
180	Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1233-1239.	0.5	5

#	ARTICLE	IF	CITATIONS
181	The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors. <i>Blood</i> , 2014, 124, 4490-4490.	0.6	5
182	Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7507-7507.	0.8	5
183	Hepatitis B Virus (HBV) Screening in Hematology/Oncology Patients Who Receive Rituximab: Continued Need for Evidence-Based Standardized Recommendations and Effective Implementation Into Clinical Practice. <i>Blood</i> , 2012, 120, 970-970.	0.6	5
184	Radioimmunotherapy in Non-Hodgkin's Lymphoma: Trials of Yttrium 90â€“Labeled Ibritumomab Tiuxetan and Beyond. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, S11-S15.	2.1	4
185	University of Chicago phase II consortium trial of selumetinib (<scp>MEK</scp>i) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , 2018, 181, 264-267.	1.2	4
186	Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality. <i>Journal of Clinical Oncology</i> , 2020, 38, 4131-4134.	0.8	4
187	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011, 118, 94-94.	0.6	4
188	Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2014, 124, 3170-3170.	0.6	4
189	Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine. <i>Blood</i> , 2015, 126, 5408-5408.	0.6	4
190	Curing Hodgkin's lymphoma: quantity and quality. <i>Lancet Oncology</i> , The, 2009, 10, 1134-1135.	5.1	3
191	Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , 2018, 59, 1976-1980.	0.6	3
192	Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 436-446.	0.4	3
193	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
194	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. <i>Blood</i> , 2011, 118, 879-879.	0.6	3
195	The Brutonâ€™s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations. <i>Blood</i> , 2014, 124, 1772-1772.	0.6	3
196	T-Cell Non-Hodgkinâ€™s Lymphoma. , 2006, , 161-220.		3
197	Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey. <i>European Journal of Cancer Care</i> , 2022, 31, e13553.	0.7	3
198	Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage. <i>JCO Oncology Practice</i> , 2022, 18, 491-497.	1.4	3

#	ARTICLE	IF	CITATIONS
199	The Novel 2nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.. Blood, 2009, 114, 285-285.	0.6	2
200	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	0.6	2
201	Targeting The Interactions Of Fatty Acid Metabolism With PI3K/mTOR and MAPK As a Novel Therapeutic Strategy In Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2013, 122, 5133-5133.	0.6	2
202	Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival. Blood, 2010, 116, 3124-3124.	0.6	2
203	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. Blood, 2012, 120, 2728-2728.	0.6	2
204	End of induction positron emission tomography complete response (PETâ€œCR) as a surrogate for progressionâ€œfree survival in previously untreated follicular lymphoma. British Journal of Haematology, 2022, 198, 333-337.	1.2	2
205	Reply to D. Dierickx et al. Journal of Clinical Oncology, 2010, 28, e367-e368.	0.8	1
206	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	0.6	1
207	A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 1555-1564.	0.6	1
208	Optimizing Decision Making in Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 265-273.	0.2	1
209	Long-Term Follow-Up of Recombinant Human Erythropoietin (epoetin)Induced Pure Red Cell Aplasia (PRCA): A Comparison of Data Collected through Active and Passive Pharmacovigilance Efforts.. Blood, 2004, 104, 5319-5319.	0.6	1
210	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. Blood, 2009, 114, 2708-2708.	0.6	1
211	Mitochondrial-Mediated Apoptosis in Lymphoma by the Diterpenoid Lactone Andrographolide (Andro), the Active Component of Andrographolis Paniculata.. Blood, 2009, 114, 2710-2710.	0.6	1
212	A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADEÂ®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL. Blood, 2011, 118, 1646-1646.	0.6	1
213	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. Blood, 2011, 118, 2625-2625.	0.6	1
214	A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. Blood, 2012, 120, 1640-1640.	0.6	1
215	Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder (HL-PTLD) after Solid Organ Transplant (SOT): A Comprehensive and Comparative Analysis of Disease Characteristics, Prognosis, and Survival. Blood, 2014, 124, 502-502.	0.6	1
216	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1

#	ARTICLE	IF	CITATIONS
217	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	0.6	1
218	PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells.. Blood, 2009, 114, 2713-2713.	0.6	1
219	Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project.. Blood, 2011, 118, 4112-4112.	0.6	1
220	Fatty Acid Metabolism in Diffuse Large B-Cell Lymphoma (DLBCL): Interaction with Oncogenic Cell Signaling Pathways and the Identification of a Novel Treatment Paradigm.. Blood, 2012, 120, 2711-2711.	0.6	1
221	The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.. Blood, 2012, 120, 2877-2877.	0.6	1
222	The Impact of Race, Age, and Sex in Follicular Lymphoma (FL): A Comprehensive SEER Analysis in the Pre- and Post-Rituximab Eras. Blood, 2012, 120, 1576-1576.	0.6	1
223	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 864-864.	0.6	1
224	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1
225	Hodgkin lymphoma: epidemiology, diagnosis, and treatment. , 0, , 367-403.		1
226	The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHLâ€™Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study.. Journal of Clinical Oncology, 2022, 40, e24004-e24004.	0.8	1
227	T-cell lymphoma. , 2001, , 215-232.		0
228	T-cell non-Hodgkin lymphoma. , 0, , 226-253.		0
229	Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. Cancer Treatment and Research Communications, 2017, 11, 1-5.	0.7	0
230	Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?. Lancet Haematology,the, 2018, 5, e186-e187.	2.2	0
231	Dramatic and Sustained Hematologic Complete Remission with Denileukin Diftitox (ONTAKÂ®) in a Patient with Refractory Adult T-Cell Leukemia (ATL).. Blood, 2005, 106, 4638-4638.	0.6	0
232	Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (ZevalinÂ®); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td Rituximab-Refractory Follicular Non- Hodgkinâ€™s Lymphoma (NHL).. Blood, 2005, 106, 2450-2450.	0.6	0
233	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkinâ€™s Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. Blood, 2005, 106, 5455-5455.	0.6	0
234	Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkinâ€™s Disease (HD), Indolent Non-Hodgkinâ€™s Lymphoma (INHL) and Aggressive Non-Hodgkinâ€™s Lymphoma (ANHL).. Blood, 2006, 108, 3332-3332.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Motexafin Gadolinium (MGD) Induces Oxidant Stress and Downregulates Both Pro and Anti-Oxidant Genes in the Ramos Lymphoma Cell Line: Signaling through p53 Mediated Pathways.. Blood, 2007, 110, 4429-4429.	0.6	0
236	Hypoxia-Inducible Factor-Alpha (HIF-1 $\alpha$ ) Activation in Non-Hodgkin's Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).. Blood, 2007, 110, 3587-3587.	0.6	0
237	All Trans Retinoic Acid Nanodisks Enhance Retinoic Acid Receptor-Mediated Apoptosis and Cell Cycle Arrest in Mantle Cell Lymphoma.. Blood, 2009, 114, 3722-3722.	0.6	0
238	A Comprehensive Identification of the MicroRNA Transcriptome and Its Application in B Cell Malignancies.. Blood, 2009, 114, 2403-2403.	0.6	0
239	Burkitt Lymphoma and Leukemia. , 2011, , 175-210.		0
240	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 803-803.	0.6	0
241	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. Blood, 2011, 118, 433-433.	0.6	0
242	Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome.. Blood, 2011, 118, 3668-3668.	0.6	0
243	Integration of Rituximab and Liposomal Doxorubicin (DOXIL <sup>®</sup> ) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study. Blood, 2011, 118, 2669-2669.	0.6	0
244	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin's Lymphoma. Blood, 2011, 118, 4499-4499.	0.6	0
245	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. Journal of Clinical Oncology, 2012, 30, 8060-8060.	0.8	0
246	The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study.. Journal of Clinical Oncology, 2012, 30, 8080-8080.	0.8	0
247	The impact of race, age, and sex in follicular lymphoma (FL): A comprehensive SEER analysis in the pre- and post-rituximab (R) eras.. Journal of Clinical Oncology, 2012, 30, 8072-8072.	0.8	0
248	Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor. Blood, 2012, 120, 1646-1646.	0.6	0
249	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. Blood, 2012, 120, 2024-2024.	0.6	0
250	A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE <sup>®</sup> ) Therapy for Untreated High Tumor Burden Indolent Non-Hodgkin Lymphoma (NHL). Blood, 2012, 120, 1642-1642.	0.6	0
251	The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models.. Blood, 2012, 120, 2767-2767.	0.6	0
252	Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL).. Blood, 2012, 120, 2694-2694.	0.6	0

#	ARTICLE	IF	CITATIONS
253	The Impact of Cigarette Smoking On Overall Survival in Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 5100-5100.	0.6	0
254	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. <i>Blood</i> , 2012, 120, 898-898.	0.6	0
255	Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma. <i>Modern Chemotherapy</i> , 2013, 02, 57-65.	0.5	0
256	Hodgkin lymphoma-like post-transplant lymphoproliferative disorder (HL-PTLD): Characteristics, survival, and prognostication in a large U.S. cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8572-8572.	0.8	0
257	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8545-8545.	0.8	0
258	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19561-e19561.	0.8	0
259	The Management of Older Patients with Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015, , 271-286.	0.2	0
260	Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5924-5924.	0.6	0
261	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014, 124, 1703-1703.	0.6	0
262	Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL). <i>Blood</i> , 2014, 124, 3120-3120.	0.6	0
263	Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. <i>Blood</i> , 2014, 124, 2595-2595.	0.6	0
264	A Comparative Oncology Study of Canine and Human Genomics and Proteomics in Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and Therapeutic Target Discovery. <i>Blood</i> , 2014, 124, 3019-3019.	0.6	0
265	An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , 2015, 126, 2635-2635.	0.6	0
266	Periodontal Disease and Risk of Non Hodgkin Lymphoma (NHL) in the Health Professionals Follow-up Study (HPFS). <i>Blood</i> , 2015, 126, 5024-5024.	0.6	0
267	A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery. <i>Blood</i> , 2015, 126, 3883-3883.	0.6	0
268	Managing Lymphoma During Pregnancy. , 2016, , 159-173.		0
269	Health-related quality of life (HRQL) in Hodgkin lymphoma (HL): A systematic review (SR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 234-234.	0.8	0
270	Circulating microRNAs Predict the Initiation of NHL in a Novel In Vivo Model: Impact of Age and Sex Via a Systems Biology Approach. <i>Blood</i> , 2016, 128, 4114-4114.	0.6	0



#	ARTICLE	IF	CITATIONS
271	Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.. Journal of Clinical Oncology, 2019, 37, 6511-6511.	0.8	0
272	The Management of Older Patients with Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 297-315.	0.2	0
273	Comparative Analysis of Flow Cytometric Techniques in Assessment of ZAP-70 Expression in Relation to IgV H Mutational Status in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2007, 127, 182-191.	0.4	0
274	Improving outcomes in PTLD. Oncology, 2010, 24, 944, 946-7.	0.4	0
275	Cancer Immunotherapy During Pregnancy for Relapsed Lymphoma. Oncology Times, 2022, 44, 1,16-16.	0.1	0